iSpecimen Announces New Lab In New York

iSpecimen is glad to report the addition of a reference lab in New York this year. The company’s primary purpose is to support commercial and government customers specializing in COVID-19. Both Omicron and Delta assays will also be investigated in this laboratory. After updating the news, the company’s stock market is gaining momentum, by 4%, trading at $ 7.18 while the previous price was closed at $ 6.81.


Since 2020, the company has been hard at work, delivering serum samples to the US Centers for Disease Control and Prevention (CDC) to aid researchers in tracking antibody formation for prospective immunity guidance. In this case, about 600 positive samples of SARS-CoV-2 serum and 100 negative ones were sent to the CDC. COVID-19 is a topic on which iSpecimen collaborates closely with the research community; as you may be aware, the virus is still spreading worldwide. Since the epidemic’s beginning, iSpecimen has provided over 15,000 samples for over 200 COVID-related initiatives, respectively. And the company’s market cap is represented over 61 million dollars.